Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL64077 | 1.00 | LMNA (0.40) | LMNATSHRKDM4ETDP1THRB | |
| SCHEMBL815447 | 1.00 | LMNA (0.40) | LMNATSHRKDM4ETDP1THRB | |
| SCHEMBL506811 | 1.00 | LMNA (0.40) | LMNATSHRKDM4ETDP1THRB | |
| SCHEMBL817697 | 1.00 | LMNA (0.40) | LMNATSHRKDM4ETDP1THRB | |
| SCHEMBL716297 | 1.00 | LMNA (0.40) | LMNATSHRKDM4ETDP1THRB | |
| SCHEMBL506073 | 1.00 | LMNA (0.40) | LMNATSHRKDM4ETDP1THRB | |
| SCHEMBL816970 | 1.00 | LMNA (0.40) | LMNATSHRKDM4ETDP1THRB | |
| SCHEMBL817265 | 1.00 | LMNA (0.40) | LMNATSHRKDM4ETDP1THRB | |
| SCHEMBL815543 | 1.00 | LMNA (0.40) | LMNATSHRKDM4ETDP1THRB | |
| SCHEMBL61566 | 1.00 | LMNA (0.40) | LMNATSHRKDM4ETDP1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115814140-B | Antibacterial wound dressing with drainage and anti-adhesion functions and preparation method thereof | 电子科技大学 | 2024-04-12 | — | — | CN | claimed |
| CN-116019966-A | Wound dressing with tissue fluid discharge and blood scab adhesion prevention functions and preparation method thereof | 电子科技大学 | 2023-04-28 | — | — | CN | claimed |
| CN-115814140-A | Antibacterial wound dressing with drainage and anti-adhesion functions and preparation method thereof | 电子科技大学 | 2023-03-21 | — | — | CN | claimed |
| CN-109704626-B | Organic fluorine modified glycol amine substituted polycarboxylic acid cement grinding aid and preparation method thereof | 湖南辰砾新材料有限公司 | 2021-04-02 | — | — | CN | claimed |
| US-7276567-B2 | Heterocyclic substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-10-02 | — | — | US | claimed |
| US-7247687-B2 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-07-24 | — | — | US | claimed |
| EP-1521758-B1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2006-05-24 | — | — | EP | claimed |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-03-02 | — | — | US | claimed |
| EP-1521758-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | Exxonmobil Chemical Patents Inc. (US) | 2005-04-13 | — | — | EP | claimed |
| EP-1144537-B1 | ULTRAPHOBIC SURFACE | SUNYX SURFACE NANOTECHNOLOGIES (DE) | 2004-03-17 | — | — | EP | claimed |
| WO-2004007509-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-01-22 | — | — | WO | claimed |
| US-6280749-B1 | FOR USE IN PAINTS, SYNTHETIC RESINS, SYNTHETIC AND NATURAL RUBBERS, POLISHING AGENTS, SURFACE-RELEASE AGENTS AND COSMETIC OR TOILETRY PREPARATIONS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2001-08-28 | — | — | US | claimed |
| CN-115814140-B | Antibacterial wound dressing with drainage and anti-adhesion functions and preparation method thereof | 电子科技大学 | 2024-04-12 | — | — | CN | disclosed |
| WO-2024053720-A1 | NUCLEIC ACID FOR TRANSFECTION | ＡＧＣ株式会社 | 2024-03-14 | — | — | WO | disclosed |
| EP-4306572-A1 | POLYMER HAVING HALOGEN-CONTAINING SEGMENT AND PHARMACEUTICAL COMPOSITION USING SAME | AGC INC. (JP) | 2024-01-17 | — | — | EP | disclosed |
| US-20240009224-A1 | ACYCLIC THREONINOL NUCLEIC ACID | THE UNIVERSITY OF TOKYO (JP) | 2024-01-11 | — | — | US | disclosed |
| EP-0002004-B1 | PROCESS FOR THE MANUFACTURE OF FLUORINATED CATIONIC COMPOUNDS AND THEIR USE AS SURFACTANTS | CIBA-GEIGY AG (CH) | 1982-03-24 | — | — | EP | disclosed |
| EP-0002004-A1 | Process for the manufacture of fluorinated cationic compounds and their use as surfactants | CIBA-GEIGY AG (CH) | 1979-05-30 | — | — | EP | disclosed |
| US-4082719-A | ORGANOSILICON AND ALUMINUM COMPOUNDS, CURING CATALYST | DOW CORNING CORPORATION (US) | 1978-04-04 | — | — | US | disclosed |
| US-3971747-A | ORGANO-SILICON, EPOXIDE, ALUMINUM CONTAINING CATALYST | DOW CORNING CORPORATION (US) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | MLX, LOX, LMTK3 | LMNA 178/4885TSHR 4680/4885KDM4E 1868/4885 |
| US-20240009224-A1 | ACYCLIC THREONINOL NUCLEIC ACID | NSUN2, TRDMT1, SLC29A2 | LMNA 111/4885TSHR 2563/4885KDM4E 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.